Literature DB >> 4632661

Monitoring serum gold values to improve chrysotherapy in rheumatoid arthritis.

A Lorber, C J Atkins, C C Chang, Y B Lee, J Starrs, R A Bovy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4632661      PMCID: PMC1006063          DOI: 10.1136/ard.32.2.133

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  SOME PHYSIOLOGICAL IMPLICATIONS OF GOLD IN SERUM AND URINE CONCENTRATIONS IN CHRYSOTHERAPY.

Authors:  J F GOODWIN
Journal:  J Mich State Med Soc       Date:  1964-06

2.  Increasing the effectiveness of gold therapy in rheumatoid arthritis.

Authors:  R T SMITH; W P PEAK; K M KRON; I F HERMANN; R A DELTORO; M GOLDMAN
Journal:  J Am Med Assoc       Date:  1958-07-05

3.  METABOLISM, TOXICITY AND MANNER OF ACTION OF GOLD COMPOUNDS USED IN THE TREATMENT OF ARTHRITIS. I. HUMAN PLASMA AND SYNOVIAL FLUID CONCENTRATION AND URINARY EXCRETION OF GOLD DURING AND FOLLOWING TREATMENT WITH GOLD SODIUM THIOMALATE, GOLD SODIUM THIOSULFATE, AND COLLOIDAL GOLD SULFIDE.

Authors:  R H Freyberg; W D Block; S Levey
Journal:  J Clin Invest       Date:  1941-07       Impact factor: 14.808

4.  Studies with radioactive gold.

Authors:  J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1961-12       Impact factor: 19.103

5.  Effect of gold salts and other drugs on the release and activity of lysosomal hydrolases.

Authors:  R S Ennis; J L Granda; A S Posner
Journal:  Arthritis Rheum       Date:  1968-12

6.  Gold determination in biological fluids by atomic absorption spectrophotometry: application to chrysotherapy in rheumatoid arthritis patients.

Authors:  A Lorber; R L Cohen; C C Chang; H E Anderson
Journal:  Arthritis Rheum       Date:  1968-04

7.  Transport of gold in the body.

Authors:  E G McQueen; P W Dykes
Journal:  Ann Rheum Dis       Date:  1969-07       Impact factor: 19.103

8.  The effect of gold salt on lysosomal enzymes of the peritoneal macrophage.

Authors:  R H Persellin; M Ziff
Journal:  Arthritis Rheum       Date:  1966-02
  8 in total
  14 in total

1.  Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro.

Authors:  C J Danpure; D A Fyfe; J M Gumpel
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

2.  Proceedings: Factors governing safety and success of gold salt therapy in rheumatoid arthritis (RA). A prospective study.

Authors:  P De Bosset; T Bitter
Journal:  Ann Rheum Dis       Date:  1975-04       Impact factor: 19.103

Review 3.  Monitoring gold plasma levels in rheumatoid arthritis.

Authors:  A Lorber
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

4.  Tissue gold levels after chrysotherapy.

Authors:  R Grahame; R Billings; M Laurence; V Marks; P J Wood
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

5.  Gold binding to blood cells and serum proteins during chrysotherapy.

Authors:  R J van de Stadt; B Abbo-Tilstra
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

Review 6.  Mechanisms of action of gold.

Authors:  J H Leibfarth; R H Persellin
Journal:  Agents Actions       Date:  1981-11

7.  Gold in erythrocytes, whole blood, and plasma during long-term chrysotherapy.

Authors:  S M Pedersen; P M Graabaek
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

Review 8.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

9.  Auranofin. New oral gold compound for treatment of rheumatoid arthritis.

Authors:  A E Finkelstein; D T Walz; V Batista; M Mizraji; F Roisman; A Misher
Journal:  Ann Rheum Dis       Date:  1976-06       Impact factor: 19.103

Review 10.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.